Ganaxolone ( DrugBank: Ganaxolone )
4 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 145 | ウエスト症候群 | 5 |
| 152 | ＰＣＤＨ19関連症候群 | 10 |
| 158 | 結節性硬化症 | 3 |
| 206 | 脆弱Ｘ症候群 | 2 |
145. ウエスト症候群
臨床試験数 : 43 / 薬物数 : 52 - (DrugBank : 15) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 26
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2006-004285-13-CZ (EUCTR) | 11/05/2007 | 30/03/2007 | A double-blind, placebo-controlled, dose-ranging clinical study to evaluate the safety, tolerability, and antiepileptic activity of ganaxolone in treatment of patients with infantile spasms. | A double-blind, placebo-controlled, dose-ranging clinical study to evaluate the safety, tolerability, and antiepileptic activity of ganaxolone in treatment of patients with infantile spasms. | Infantile spasms MedDRA version: 9.1;Level: LLT;Classification code 10021750;Term: Infantile spasms | Product Name: Ganaxolone Other descriptive name: Ganaxolone | Marinus Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 54 | Czech Republic | |||
| 2 | EUCTR2006-004286-33-CZ (EUCTR) | 11/05/2007 | 30/03/2007 | An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spasms. | An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spasms. | Infantile spasms MedDRA version: 9.1;Level: LLT;Classification code 10021750;Term: Infantile spasms | Product Name: Ganaxolone Product Code: SPT3162 Other descriptive name: Ganaxolone | Marinus Pharmceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 54 | Czech Republic | |||
| 3 | NCT00441896 (ClinicalTrials.gov) | January 2007 | 27/2/2007 | A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms | A Double-blind, Placebo-controlled, Dose-ranging Clinical Study to Evaluate the Safety, Tolerability, and Antiepileptic Activity of Ganaxolone in Treatment of Patients With Infantile Spasms | Infantile Spasms | Drug: Ganaxolone;Other: Placebo | Marinus Pharmaceuticals | NULL | Completed | 4 Months | 24 Months | All | 56 | Phase 2 | United States |
| 4 | NCT00442104 (ClinicalTrials.gov) | January 2007 | 27/2/2007 | Open-label Extension to Protocol 1042-0500 | An Open-label Clinical Study to Evaluate the Safety and Antiepileptic Activity of Ganaxolone in Treatment of Patients Diagnosed With Infantile Spasms. | Infantile Spasms | Drug: Ganaxolone | Marinus Pharmaceuticals | NULL | Terminated | 4 Months | 24 Months | All | 54 | Phase 2 | United States |
| 5 | EUCTR2006-004286-33-PL (EUCTR) | 04/06/2007 | An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spansms. | An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spansms. | Infantile spasms MedDRA version: 9.1;Level: LLT;Classification code 10021750;Term: Infantile spasms | Product Name: Ganaxolone Product Code: SPT3162 | Marinus Pharmceuticals, Inc. | NULL | NA | Female: yes Male: yes | 54 | Phase 2 | Czech Republic;Poland |
152. ＰＣＤＨ19関連症候群
臨床試験数 : 10 / 薬物数 : 7 - (DrugBank : 1) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-004496-12-GB (EUCTR) | 14/01/2020 | 18/11/2019 | A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsy | A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | protocadherin 19 (PCDH19)-related epilepsy MedDRA version: 20.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT3162 INN or Proposed INN: GANAXOLONE | Marinus Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 70 | Phase 3 | United States;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Poland;Australia;Denmark;Germany;Netherlands | ||
| 2 | EUCTR2018-004496-12-HU (EUCTR) | 13/01/2020 | 04/11/2019 | A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsy | A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | protocadherin 19 (PCDH19)-related epilepsy MedDRA version: 20.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT3162 INN or Proposed INN: GANAXOLONE | Marinus Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 70 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United States;Spain;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Poland;Belgium;Australia;Denmark;Germany;Netherlands | ||
| 3 | EUCTR2018-004496-12-FR (EUCTR) | 26/09/2019 | 29/04/2019 | A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsy | A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | protocadherin 19 (PCDH19)-related epilepsy MedDRA version: 20.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT316 INN or Proposed INN: GANAXOLONE | Marinus Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 50 | Phase 3 | United States;France;Hungary;Poland;Spain;Australia;Netherlands;Italy;United Kingdom | ||
| 4 | EUCTR2018-004496-12-NL (EUCTR) | 23/09/2019 | 05/06/2019 | A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsy | A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | protocadherin 19 (PCDH19)-related epilepsy MedDRA version: 20.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT3162 INN or Proposed INN: GANAXOLONE | Marinus Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 30 | Phase 2 | United States;Czechia;Spain;Israel;Italy;United Kingdom;France;Hungary;Belgium;Poland;Australia;Denmark;Netherlands;Germany | ||
| 5 | EUCTR2018-004496-12-IT (EUCTR) | 26/06/2019 | 20/01/2021 | A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsy | A double-blind, randomized, placebo-controlled trial of adjunctiveganaxolone treatment in female children with protocadherin 19 (PCDH19)- related epilepsy followed by long-term open-label treatment - N/A | protocadherin 19 (PCDH19)-related epilepsy MedDRA version: 20.0;Level: LLT;Classification code 10032062;Term: Other forms of epilepsy, with intractable epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ganaxolone Product Code: [CCD 1042, MD 9150000, Mepalon 1042, SPT316] INN or Proposed INN: GANAXOLONE | Marinus Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 70 | Phase 3 | United States;Czechia;Israel;Italy;United Kingdom;France;Hungary;Belgium;Poland;Australia;Denmark;Germany;Netherlands | ||
| 6 | NCT03865732 (ClinicalTrials.gov) | May 17, 2019 | 5/3/2019 | Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study) | A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy Followed by Long-term Open-label Treatment. | PCDH19-Related Epilepsy | Drug: Ganaxolone;Drug: Placebo | Marinus Pharmaceuticals | NULL | Active, not recruiting | 1 Year | 17 Years | Female | 25 | Phase 2 | United States;Hungary;Italy;Netherlands;Poland;Australia;France |
| 7 | EUCTR2015-001324-36-IT (EUCTR) | 05/06/2015 | 16/04/2015 | Pilot, multicenter study to evaluate the efficacy of the ganaxolone in female children with PCDH19 Pediatric Epilepsy. | A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children with PCDH19 Female Pediatric Epilepsy | PCDH19 Female Pediatric Epilepsy (FPE) MedDRA version: 18.0;Level: LLT;Classification code 10032062;Term: Other forms of epilepsy, with intractable epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT316 INN or Proposed INN: GANAXOLONE Other descriptive name: Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3ß-methyl-5a-pregnan-20-one) Product Name: ganaxolone Product Code: CCD 1042 INN or Proposed INN: GANAXOLONE Other descriptive name: Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3ß-methyl-5a-pregnan-20-one) | Marinus Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: no | 10 | United States;Italy | |||
| 8 | NCT02358538 (ClinicalTrials.gov) | March 2015 | 30/1/2015 | A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies | A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment | Epilepsy | Drug: Ganaxolone | Marinus Pharmaceuticals | NULL | Active, not recruiting | 2 Years | 18 Years | All | 30 | Phase 2 | United States;Italy |
| 9 | EUCTR2018-004496-12-PL (EUCTR) | 01/08/2019 | A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsy | A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | protocadherin 19 (PCDH19)-related epilepsy MedDRA version: 20.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT3162 INN or Proposed INN: GANAXOLONE | Marinus Pharmaceuticals, Inc. | NULL | NA | Female: yes Male: no | 30 | Phase 2 | United States;Czechia;Spain;Ireland;Italy;United Kingdom;France;Hungary;Poland;Belgium;Australia;Denmark;Germany;Netherlands | |||
| 10 | EUCTR2018-004496-12-DK (EUCTR) | 07/11/2019 | A clinical study with an investigational drug called ganaxolone in female children with protocadherin 19 (PCDH19)-related epilepsy | A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment | protocadherin 19 (PCDH19)-related epilepsy MedDRA version: 20.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT316 INN or Proposed INN: GANAXOLONE | Marinus Pharmaceuticals, Inc. | NULL | NA | Female: yes Male: no | 70 | Phase 3 | United States;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Hungary;Poland;Belgium;Denmark;Australia;Germany;Netherlands |
158. 結節性硬化症
臨床試験数 : 112 / 薬物数 : 71 - (DrugBank : 19) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05604170 (ClinicalTrials.gov) | May 16, 2022 | 5/10/2022 | Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC OLE) | Tuberous Sclerosis Complex | Drug: Ganaxolone | Marinus Pharmaceuticals | NULL | Enrolling by invitation | 1 Year | 65 Years | All | 169 | Phase 3 | United States |
| 2 | NCT05323734 (ClinicalTrials.gov) | April 1, 2022 | 21/3/2022 | Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy | A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC) | Tuberous Sclerosis Complex | Drug: Ganaxalone;Drug: Placebo | Marinus Pharmaceuticals | NULL | Recruiting | 1 Year | 65 Years | All | 162 | Phase 3 | United States;Canada;France;Germany;Israel;Italy;Spain;United Kingdom |
| 3 | NCT04285346 (ClinicalTrials.gov) | April 8, 2020 | 18/2/2020 | Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) | A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) in Tuberous Sclerosis Complex-related Epilepsy Followed by Long-term Treatment (Part B) | Tuberous Sclerosis | Drug: Ganaxolone | Marinus Pharmaceuticals | NULL | Completed | 2 Years | 65 Years | All | 24 | Phase 2 | United States |
206. 脆弱Ｘ症候群
臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-000251-89-BE (EUCTR) | 22/10/2014 | 18/08/2014 | A clinical study with an investigational drug called ganaxolone in children with fragile X syndrome | A controlled double-blind crossover trial of ganaxolone in children with fragile X syndrome - GNX study | behavioral problems in children with fragile X syndrome MedDRA version: 17.0;Level: PT;Classification code 10017324;Term: Fragile X syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Ganaxolone Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT316 INN or Proposed INN: GANAXOLONE | Antwerp University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 60 | United States;Belgium | |||
| 2 | NCT01725152 (ClinicalTrials.gov) | November 2012 | 7/11/2012 | Ganaxolone Treatment in Children With Fragile X Syndrome | A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome | Fragile x Syndrome | Drug: Ganaxolone;Drug: Placebo | Marinus Pharmaceuticals | University of California, Davis;U.S. Army Medical Research and Development Command | Completed | 6 Years | 17 Years | All | 59 | Phase 2 | United States;Belgium |